Liabilities / Assets
38th percentile
Higher debt load relative to assets than 38% of similar nonprofits.
Neuroendocrine Cancer Foundation
990 • Fiscal year 2023 • EIN 20-0062062
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.00x
Liabilities / Revenue
40th percentile
Higher debt load relative to revenue than 40% of similar nonprofits.
Net Margin
59th percentile
Higher net margin than 59% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
49th percentile
Faster asset growth than 49% of similar nonprofits.
Revenue Growth
74th percentile
Faster revenue growth than 74% of similar nonprofits.
Balance Sheet
Assets
Up$609,253
Up $18,846 (+3.2%) from 2022
Net Assets
Up$607,345
Up $27,616 (+4.8%) from 2022
Liabilities
Down$1,908
Down $8,770 (-82%) from 2022
Revenue And Expenses
Revenue
Up$286,106
Up $67,735 (+31%) from 2022
Expenses
Up$260,412
Up $78,113 (+43%) from 2022
Net Income
Down$25,694
Down $10,378 (-29%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
The mission of the learn advocate connect neuroendocrine tumor society lacnets is to provide a community of support and education for patients those with neuroendocrine cancer and to advocate for all people impacted by this rare disease by expanding awareness and voicing the patients perspective in collaborative dialogue continued sch. O
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $609,253
- Liabilities
- $1,908
- Net assets
- $607,345
- Revenue
- $286,106
- Expenses
- $260,412
- Net income
- $25,694